1. Home
  2. Clinical Topics
  3. FDA approves treatment for adults with relapsed or refractory acute myeloid leukemia
Clinical TopicsDrugs and DevicesWeb Exclusives
treatment adults acute myeloid leukemia

FDA approves treatment for adults with relapsed or refractory acute myeloid leukemia

Share

On Nov. 28, the FDA approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Read more via U.S. Food & Drug Administration.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts